Key result
Angiotensin II induces MLC-2v gene transcription via enhanced binding of the Nishéd-NFATc4-p300 complex to an intronic regulatory element, an effect abolished by the AT1 receptor antagonist losartan.
The study identifies a specific intronic regulatory element and transcription factor complex (Nishéd/NFATc4/p300) as a direct target of Angiotensin II signaling in the up-regulation of the MLC-2v gene during cardiac hypertrophy.
Answers are grounded in this paper and cite their sources.
Suggests a losartan-sensitive transcriptional target in hypertrophy; leaves open human disease relevance.
Transcriptional up-regulation of the myosin light chain-2 (MLC-2v) gene is an established marker for hypertrophic response in cardiomyocytes. Despite the documentation on the role of several cis-elements in the MLC-2v gene and their cognate proteins in transcription, the mechanism that dictates the preferential increase in MLC-2v gene expression during myocardial hypertrophy has not been delineated. Here we describe the properties of a cardiac specific intronic activator element (IRE) that shares sequence homology with the repressor element, the cardiac specific sequence, in the chicken MLC-2v gene. The transcription factor, Nishéd, that recognizes both IRE and the cardiac specific sequence potentiates the transcription of the MLC-2v gene via interaction with another transcription factor, nuclear factor of activated T cells, and the co-activator p300 at the IRE site. Angiotensin II (Ang II), a potent agonist of hypertrophy, causes induction of the MLC-2v gene transcription, which correlates well with the enhanced binding of Nishéd-nuclear factor of the activated T cells-p300 complex to IRE in the gel mobility shift assay. Losartan, an antagonist of Ang II receptor (AT1), abolishes the agonist-dependent stimulation of IRE/protein interaction and the consequent increase in MLC-2v gene transcription. These results together have thus established a transcriptional role of IRE as a direct target sequence of Ang II-mediated signaling that appears to be pivotal in the mechanism underlying the up-regulation of the MLC-2v gene during cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Mathew et al. (2004) studied Cardiac hypertrophy. Angiotensin II and Losartan was evaluated on MLC-2v gene transcription and IRE/protein interaction. Angiotensin II induces MLC-2v gene transcription via enhanced binding of the Nishéd-NFATc4-p300 complex to an intronic regulatory element, an effect abolished by the AT1 receptor antagonist losartan.
Synapse has enriched 10 related papers. Consider them for comparative context: